StreetInsider.com News Articles

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

PISCATAWAY, N.J., Aug. 17, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global pioneer in life sciences innovation, today announced outstanding interim results for the first half of 2025, underscoring its ability to deliver profitable growth at scale through strategic globalization, differentiated technology, and relentless innovation.

Fueled by robust demand across all business segments and expansion into key international markets, GenScript achieved consolidated revenue of approximately US$518.8 million for H1 2025, reflecting an exceptional 81.9% year-over-year increase. Gross profit rose

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

Sun, 17 Aug 2025 08:01:00 -0400

Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

Fri, 08 Aug 2025 08:30:00 -0400

PISCATAWAY, N.J., Aug. 8, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global leader in life sciences innovation, today unveiled its new global brand platform: Scripting Possibilities—a future-forward identity designed to match the speed, complexity, and promise of modern biotechnology.

The brand relaunch reflects GenScript's ambition to become the most trusted partner for researchers worldwide—delivering scientific accelerations from discovery to manufacturing with speed, precision, and purpose. The new platform, visual identity, and tagline roll out globally today, on GenScript's 23rd birthday, across every region and touchpoint.

"This

GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

Fri, 08 Aug 2025 08:30:00 -0400

"This

GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

Fri, 08 Aug 2025 08:30:00 -0400

"This

GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

Fri, 08 Aug 2025 08:30:00 -0400

"This

GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

Fri, 08 Aug 2025 08:30:00 -0400

"This

GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

Fri, 08 Aug 2025 08:30:00 -0400

"This

GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

Fri, 08 Aug 2025 08:30:00 -0400

"This

GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

Fri, 08 Aug 2025 08:30:00 -0400

"This

GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader

Thu, 31 Jul 2025 22:02:00 -0400

PISCATAWAY, N.J., July 31, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that its ESG rating has been upgraded to AA from A by MSCI in recognition of the company's excellence in the areas of product safety & quality and human capital development, as well as continuous improvement in environment and governance practices.

MSCI, one of the world's largest index providers, evaluates global public and private companies on a scale from CCC (laggard) to AAA (leader), according to exposure to industry-specific ESG

GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader

Thu, 31 Jul 2025 22:02:00 -0400

MSCI, one of the world's largest index providers, evaluates global public and private companies on a scale from CCC (laggard) to AAA (leader), according to exposure to industry-specific ESG

GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader

Thu, 31 Jul 2025 22:02:00 -0400

MSCI, one of the world's largest index providers, evaluates global public and private companies on a scale from CCC (laggard) to AAA (leader), according to exposure to industry-specific ESG

GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader

Thu, 31 Jul 2025 22:02:00 -0400

MSCI, one of the world's largest index providers, evaluates global public and private companies on a scale from CCC (laggard) to AAA (leader), according to exposure to industry-specific ESG

GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader

Thu, 31 Jul 2025 22:02:00 -0400

MSCI, one of the world's largest index providers, evaluates global public and private companies on a scale from CCC (laggard) to AAA (leader), according to exposure to industry-specific ESG